Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cellular signaling pathways modulators - AntlerA Therapeutics

Next Previous
Search
Drug Profile

Research programme: cellular signaling pathways modulators - AntlerA Therapeutics

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AntlerA Therapeutics
  • Developer AntlerA Therapeutics; University of Minnesota; University of Toronto
  • Class Anti-inflammatories; Antibodies; Eye disorder therapies; Proteins
  • Mechanism of Action Signal transduction pathway modulators; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Retinopathy of prematurity
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for research development in Inflammatory-bowel-diseases in Canada (Parenteral)
  • 28 Sep 2023 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA (Parenteral)
  • 09 Jun 2021 Pharmacodynamics data from a preclinical trial in retinopathy of prematurity released by AntlerA Therapeutics, the University of Toronto and the University of Minnesota Medical School

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top